Navigation Links
United Therapeutics Corporation Reports Second Quarter 2013 Financial Results
Date:7/25/2013

>124,311$

110,39812.6

%Tyvaso

109,45881,21034.8

%Adcirca

43,72630,22444.7

%Other

3,1113,745(16.9)

%Total net revenues

$

280,606$

225,57724.4

%Revenues for the quarter ended June 30, 2013 increased by $55.0 million, compared to the same quarter in 2012. The growth in product revenues reflects the continuing increase in the number of patients being treated with our products.

Expenses

The table below summarizes research and development expense by major project and non-project components (dollars in thousands):Three Months EndedJune 30,PercentageChange20132012Project and non-project component:Cardiopulmonary

$

28,537$

22,05829.4

%Share-based compensation expense

14,1584,221235.4

%Other

11,92210,82010.2

%Total research and development expense

$

54,617$

37,09947.2

%Cardiopulmonary. The $6.5 million increase in cardiopulmonary program expense for the quarter ended June 30, 2013, compared to the same quarter in 2012, resulted from increases in expenses incurred related to the development of oral treprostinil and our TransCon once-daily injectable prostacyclin analogues.

Share-based compensation. The increase in share-based compensation of $9.9 million for the quarter ended June 30, 2013, compared to the same quarter in 2012, resulted from the appreciation in the price of our common stock.

The table below summarizes selling, general and administrative expense by major categories (dollars in thousands):Three Months Ended June 30,PercentageChange20132012Category:General and administrative

$

35,445$

31,23313.5

%Sales and marketing

17,34417,1361.2

%Share-based compensation expense

18,5764,889280.0

%Total selling, general and adminis
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. United Therapeutics Corporation to Announce Second Quarter 2013 Financial Results Before Market Open on Thursday, July 25, 2013
2. Before the Bell Scans: Pharmacyclics, United Therapeutics, Impax Laboratories, and Star Scientific
3. Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol"
4. Centre for Sight First in the United Kingdom to Utilize TrueVision® 3D Visualization During Femtosecond Laser Cataract Surgery
5. Prevagen® is the Number One Branded Memory Supplement in the United States
6. SPIE on Global Team Proposing ‘international Year of Light’ at United Nations
7. United Airlines and AltAir Fuels to Bring Commercial-Scale, Cost-Competitive Biofuels to Aviation Industry
8. Despite Lucentiss Recent Expanded Label for Diabetic Macular Edema, Avastin Remains the Preferred Intravitreal Therapy for Diabetic Macular Edema in the United States
9. Atlantic Peptides Teams Up with a United Kingdom Company to Offer cGMP Peptides and API
10. SoundConnect Announces Lync Release in the United States
11. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... phones to cars and flashlights, batteries play an ... companies constantly are seeking ways to improve battery ... using a water-based solution, researchers at the University ... efficient nuclear battery that could be used for ... in automobiles and also in complicated applications such ...
(Date:9/16/2014)... Cardioxyl Pharmaceuticals, Inc. announced today ... to be effective in animal models following oral (capsule) ... infusions that could pave the way for convenient outpatient ... at the Heart Failure Society of America,s (HFSA) 18 ... Vegas . The research, conducted in ...
(Date:9/16/2014)... Sept. 16, 2014  The Council for Entrepreneurial ... organization in the country, today released a mid-year ... It showed that in the ... startups in the technology, life science, ... investment from a variety of sources. Significant investment in ...
(Date:9/16/2014)... Arizona (PRWEB) September 16, 2014 ... develops safe and effective products to treat patients ... use of a proprietary SPACE™ Technology Platform announced ... and President will present at the White Hat ... at the Hyatt Regency Phoenix. In addition, ...
Breaking Biology Technology:Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 3CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 4Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 2Convoy Therapeutics to Present at WhiteHat Investor Conference September 18, 2014 3
... , June 17 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ... been granted its 35th U.S. Patent, # 7,731,951 entitled "Viruses for ... for treating cell proliferative disorders by administering modified vaccinia virus to ... , , ...
... June 17 ChemoCentryx, Inc., today announced that ... drug candidate CCX354 at the Annual European Congress of ... drug candidate designed to specifically target the CCR1 chemokine ... (RA).  Data demonstrating that CCX354 was safe and well ...
... Researchers at Rensselaer Polytechnic Institute have developed a ... that measure only billionths of a meter thick. ... works on nearly any surface including silicon wafers, ... manufacturing. Sang-Kee Eah, assistant professor in the ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Announces Issuance of 35th U.S. Patent 2ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR) 2ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR) 3ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR) 4Researchers develop ultra-simple method for creating nanoscale gold coatings 2
(Date:9/17/2014)... their environmental impact recently scored a major win. In ... the bags, and Governor Jerry Brown is expected to ... yielding without a fight, according to an article in ... of the American Chemical Society. , Alexander Tullo, a ... logged its first small victory in 1990 when Nantucket ...
(Date:9/17/2014)... Evolution and Yale University offers compelling support for the ... partially predict the likelihood of being diagnosed with mental ... life. The study analyzed medical records of 1.75 million ... 30 years, and adjusted for almost all other known ... Proceedings of the Royal Society, London B . ...
(Date:9/17/2014)... in Biomedical Informatics at IMIM (Hospital del Mar Medical ... (UPC) have recently published a study in eLife ... important role in the evolution of new proteins, some ... be discovered., Ribosomes produce proteins from the instructions found ... human genome is RNA containing information for the synthesis ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Parts of genome without a known function may play a key role in the birth of new proteins 2
... mountain meadows in the Pacific Northwest are declining rapidly due ... growing seasons and other factors allow trees to invade these ... wildflowers. The process appears to have been going on ... Jefferson Park, a subalpine meadow complex in the central Oregon ...
... Planck Institute for Chemical Energy Conversion (MPI CEC) and ... on a hydrogen-producing enzyme that the environment of the ... enzyme. Thus, it can very efficiently produce hydrogen, which ... research team describes their results in the journal " ...
... Calif.During the early developmental stages of vertebratesanimals that ... undergo extensive rearrangements, and some cells migrate over ... novel roles as differentiated cell types. Understanding how ... an embryo is an important and complex goal ...
Cached Biology News:Mountain meadows dwindling in the Pacific Northwest 2Temporary storage for electrons: Natural method of producing hydrogen 2Developmental bait and switch 2Developmental bait and switch 3
Rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and refrigerated within 6 hours, and processed and frozen within 24 hours. The serum is ...
SHEEP ANTI HUMAN CATHEPSIN G...
Request Info...
RABBIT ANTI TRANSFERRIN RECEPTOR...
Biology Products: